Shin et al. established gastric cancer HER2+ patient-derived xenografts (PDX, n = 5) which were treated with Trastuzumab, Pertuzumab and a novel HER2 directed antibody (1A12) as a monotherapy or dual blockade. This evidence concerns the gene ERBB2 and gastric cancer.